Trailblazing the path to transcription factors by intervening at a previously hidden region we have identified as the ‘switch site.’



To date, the collective research on transcription factors has been elusive to drug discovery. However, Flare Therapeutics has now reached a moment of light – with the prospect of forever changing the trajectory of how we treat disease.



Flareā€™s pipeline is Initially focused on precision oncology.

Our small molecules are designed to regain transcriptional control that is hijacked by cancer.




Intensity, empathy, determination, and brilliance. The Flare Therapeutics team is a living, growing, thriving organization of talented people and bright minds. We are always looking for new sparks to flame our collective fire. Learn more about our culture and join us!

  Join Us

Flare Therapeutics Presents New Translational Data in Support of Lead Asset FX-909 for the Treatment of Muscle-Invasive Urothelial Cancer at SITC 2023 Annual Meeting
--Poster presentation proposes targeting PPARG for the treatment of muscle-invasive urothelial cancer (MIUC) may help overcome resistance to immunotherapy--

  Read full story


This links to an external website.